Aurion Biotech is a US biotech with a regenerative medicine platform, developing novel therapies to restore vision to millions of people in need. This week on the podcast, we have a conversation with CEO Greg Kunst about Aurion’s pipeline, and how the company’s treatment could be the first mass-market cell therapy available.The FDA has granted the company BTD and RMAT designations for AURN001 -- the first-ever allogeneic cell therapy candidate in development to restore vision in patients...